NCT01786096View on ClinicalTrials.gov

A Safety Study of SGN-CD19A for Leukemia and Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

May 30, 2017

Study Completion Date

May 30, 2017

Conditions
Burkitt LymphomaPrecursor B-cell Lymphoblastic Leukemia-Lymphoma
Interventions
DRUG

SGN-CD19A

SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg

Trial Locations (13)

10021

Memorial Sloan Kettering Cancer Center, New York

30322

Children's Healthcare of Atlanta / Emory University, Atlanta

32224

Mayo Clinic Florida, Jacksonville

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

33701

All Children's Hospital, St. Petersburg

35233

Children's Hospital of Alabama / University of Alabama at Birmingham, Birmingham

35294

University of Alabama at Birmingham, Birmingham

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

85259

Mayo Clinic Arizona, Scottsdale

91010-3000

City of Hope National Medical Center, Duarte

02114

Massachusetts General Hospital, Boston

02215

Boston Children's Hospital, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Seagen Inc.

INDUSTRY

NCT01786096 - A Safety Study of SGN-CD19A for Leukemia and Lymphoma | Biotech Hunter | Biotech Hunter